The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.
 
Julie Nicole Graff
Honoraria - Astellas Medivation; Bayer; Bayer; Bayer; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Sanofi; Valeant/Dendreon
Consulting or Advisory Role - Exelixis
Speakers' Bureau - i3 CME
Research Funding - Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Merck Sharp & Dohme; Merck Sharp & Dohme; Sanofi
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Novartis; Pfizer; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
 
Clara Hwang
Stock and Other Ownership Interests - GE Healthcare; Johnson & Johnson
Consulting or Advisory Role - Genzyme
Research Funding - AstraZeneca; Bausch Health; Bayer; Genentech; Merck
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Sanofi
Speakers' Bureau - Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
AJ Ten Tije
Consulting or Advisory Role - Bristol-Myers Squibb
 
Aurelius Gabriel Omlin
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Janssen (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Anthony Elliott
Research Funding - Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Bayer (Inst); Janssen; Janssen (Inst); Pfizer; Pfizer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Helen Wu
Employment - MSD
Stock and Other Ownership Interests - Merck Sharp & Dohme (I)
Travel, Accommodations, Expenses - MSD RD China
 
Jeri Kim
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex